Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC

Download All
Get up to date on optimal management of HR-positive/HER2-negative advanced breast cancer by watching the on-demand Webcast and downloading slides from a dynamic expert presentation on current and emerging therapies targeting CDK4/6, PI3K, AKT, mTOR, and more!
Sara Hurvitz, MD, FACP
Sara Tolaney, MD, MPH

On-Demand Webcast

Watch this on-demand Webcast capturing expert presentations from a live CCO Webinar on the latest treatment strategies for patients with HR+/HER2- advanced breast cancer.

Downloadable Slideset

Download this short highlight slideset from a live presentation on the optimal management of HR-positive/HER2-negative advanced breast cancer today.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: July 1, 2020

Review the latest clinical data and expert guidance on leveraging CDK4/6 inhibitors for treatment of HR+/HER2- advanced breast cancer, including how to select among available agents and manage common toxicities.

Sara Hurvitz, MD, FACP Released: June 17, 2020

Get up to date on newly approved and emerging agents targeting the PI3K/AKT/mTOR pathway and ESR1 mutations in HR+/HER2- advanced breast cancer, including alpelisib, everolimus, capivasertib, SERDs, and more.

Sara Tolaney, MD, MPH Released: June 17, 2020
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings